Results 51 to 60 of about 176 (130)
Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment. However, activation of circumventing signaling pathways and quiescence may limit BCR-ABLi efficacy.
Alvina I. Khamidullina +17 more
doaj +1 more source
BACKGROUND AND OBJECTIVES: Despite the use of targeted therapy, chronic myelogenous leukemia (CML) currently remains incurable with drug therapy, with patients requiring life-long treatment.
Karen Shires +4 more
doaj +1 more source
Langerhans Cell Histiocytosis Associated With Chronic Myeloid Leukemia: A Pediatric Case Report
ABSTRACT Background Langerhans cell histiocytosis (LCH) is a rare clonal neoplasm driven by activating mutations in the MAPK pathway, leading to accumulation of pathological Langerhans cells in various tissues. LCH is increasingly associated with secondary malignancies, including leukemias, lymphomas, and solid tumors. However, chronic myeloid leukemia
Atbin Latifi, Sina Yousefian
wiley +1 more source
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) [PDF]
We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity.
Fischer, T. +13 more
openaire +3 more sources
Bosutinib in the management of chronic myelogenous leukemia
Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an ...
Keller-von Amsberg G, Schafhausen P
doaj
Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases
Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang +3 more
wiley +1 more source
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji +2 more
wiley +1 more source
ABSTRACT Background Myeloid sarcoma is a rare solid tumour of immature myeloid precursors occurring in an extramedullary site. It often presents significant diagnostic and therapeutic challenges to clinical haematologists. Case We describe a previously healthy patient who presented simultaneously with hyperleucocytic chronic myeloid leukaemia in ...
Kar Ying Yong +3 more
wiley +1 more source
Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib [PDF]
Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease.
Ćojbašić Irena +1 more
doaj +1 more source
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer +3 more
wiley +1 more source

